Alder slides as Bristol-Myers dumps clazakizumab
This article was originally published in Scrip
Executive Summary
Alder Biopharmaceuticals closed down 13.2% at $14.80 per share on 2 September after the company announced that Bristol-Myers Squibb gave up its rights to clazakizumab, a monoclonal antibody against the inflammatory cytokine interleukin-6 (IL-6).